Cargando…

Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry

Childhood high-risk neuroblastomas with MYCN gene amplification are difficult to treat effectively(1). This has focused attention on tumor-specific gene dependencies that underlie tumorigenesis and thus provide valuable targets for the development of novel therapeutics. Using unbiased genome-scale C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durbin, Adam D., Zimmerman, Mark W., Dharia, Neekesh V., Abraham, Brian J., Iniguez, Amanda Balboni, Weichert-Leahey, Nina, He, Shuning, Krill-Burger, John M., Root, David E., Vazquez, Francisca, Tsherniak, Aviad, Hahn, William C., Golub, Todd R., Young, Richard A., Look, A. Thomas, Stegmaier, Kimberly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386470/ https://www.ncbi.nlm.nih.gov/pubmed/30127528 http://dx.doi.org/10.1038/s41588-018-0191-z

Ejemplares similares

ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry
por: Wang, Lu, et al.
Publicado: (2019)

EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma
por: Durbin, Adam D., et al.
Publicado: (2022)

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53
por: Yi, Joanna S., et al.
Publicado: (2021)

Retinoic acid rewires the adrenergic core regulatory circuitry of childhood neuroblastoma
por: Zimmerman, Mark W., et al.
Publicado: (2021)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation
por: De Wyn, Jolien, et al.
Publicado: (2021)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Single-Cell Gene Network Analysis and Transcriptional Landscape of MYCN-Amplified Neuroblastoma Cell Lines
por: Mercatelli, Daniele, et al.
Publicado: (2021)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Targeting condensin, a vital spot of MYCN-amplified neuroblastoma
por: Tanno, Yuji, et al.
Publicado: (2014)

Multi-omic profiling of MYCN-amplified neuroblastoma cell-lines
por: Dassi, Erik, et al.
Publicado: (2015)

Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
por: Hald, Øyvind H., et al.
Publicado: (2018)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
por: Stolte, Björn, et al.
Publicado: (2018)

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome
por: Schmitt-Hoffner, Felix, et al.
Publicado: (2021)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2016)

Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas
por: Petrov, Ivan, et al.
Publicado: (2017)

Serine–glycine-one-carbon metabolism: vulnerabilities in MYCN-amplified neuroblastoma
por: Zhao, Erhu, et al.
Publicado: (2020)

Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
por: Valind, Anders, et al.
Publicado: (2023)

The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma
por: Wang, Donghai, et al.
Publicado: (2023)

Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain
por: He, Shuning, et al.
Publicado: (2016)

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
por: Liu, Tao, et al.
Publicado: (2022)

MYCN-amplified neuroblastoma cell-derived exosomal miR-17-5p promotes proliferation and migration of non-MYCN amplified cells
por: Chen, Weiming, et al.
Publicado: (2021)

SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells
por: Murakami-Tonami, Yuko, et al.
Publicado: (2016)

Genetic variation associated with childhood and adult stature and risk of MYCN‐amplified neuroblastoma
por: Semmes, Eleanor C., et al.
Publicado: (2020)

Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma
por: Yu, Yajie, et al.
Publicado: (2021)

Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression
por: Carter, R, et al.
Publicado: (2012)

The protective autophagy activated by GANT-61 in MYCN amplified neuroblastoma cells is mediated by PERK
por: Wang, Jing, et al.
Publicado: (2018)

MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling
por: Dzieran, Johanna, et al.
Publicado: (2018)

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma()
por: Felgenhauer, Joshua, et al.
Publicado: (2018)

Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line
por: López-Carrasco, Amparo, et al.
Publicado: (2020)

Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
por: Orienti, Isabella, et al.
Publicado: (2020)

MUC15 is an independent prognostic factor that promotes metastases of MYCN non-amplified neuroblastoma
por: Guo, Huiqin, et al.
Publicado: (2023)

LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma
por: Alborzinia, Hamed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lcpiaj7r0v83364q8clq9chfc7